Inclusion Criteria:  Major Multiple Sclerosis (MS) Patients RR MS patients without treatment (early stage disease) Or RR MS patients treated with first-line compounds (IFNβ, glatiramer acetate, teriflunomide and dimethyl fumarate, ...).  Or RR MS patients treated with second-line compounds (natalizumab and fingolimod, ...) RR MS patients treated with third-line compounds (alemtuzumab, ...) Or Patients with progressive MS  Patients who have read and understood the information letter and signed the consent form Person affiliated to a social security system  Exclusion Criteria:  Patients under 18 years of age or over 65 years of age, Patients who have benefited from immunosuppressive treatments for other autoimmune or cancerous pathologies, Patients receiving treatments for multiple sclerosis and participating in phase 2, 3 or 4 protocols will be excluded. Patients who have been treated for less than 1 year with cladribine, daclizumab, ocrelizumab, rituximab will be excluded. Patients who have received mitoxantrone or a stem cell transplant, Regulatory Criteria : Person deprived of liberty by an administrative or judicial decision Person placed under legal protection, sub-tutorship or curatorship